Biography
|
INSTITUTION AND LOCATION |
DEGREE (if applicable)
|
Completion Date MM/YYYY
|
FIELD OF STUDY
|
|
University of Auckland |
BSc(HONS) |
1989 |
Medicine |
|
University of Auckland |
MBChB |
1991 |
Medicine |
|
Royal North Shore Hospital, Australia |
|
1992-1996 |
Internship, General Medicine/Surgery |
|
The Royal Australasian College of Physicians, Australia |
FRACP |
1996-1999 |
Medical Residency, Medicine |
|
Toronto Western...view more |
|
INSTITUTION AND LOCATION |
DEGREE (if applicable)
|
Completion Date MM/YYYY
|
FIELD OF STUDY
|
|
University of Auckland |
BSc(HONS) |
1989 |
Medicine |
|
University of Auckland |
MBChB |
1991 |
Medicine |
|
Royal North Shore Hospital, Australia |
|
1992-1996 |
Internship, General Medicine/Surgery |
|
The Royal Australasian College of Physicians, Australia |
FRACP |
1996-1999 |
Medical Residency, Medicine |
|
Toronto Western Hospital, Toronto, Canada |
|
2000-2001 |
Nuclear medicine Fellow |
|
Staff Specialist Nuclear Medicine, Concord Hospital, Sydney |
FAANMS |
2001-2012 |
|
|
Auckland University |
MD |
2014 completed |
Thesis in Nuclear Cardiology |
A. Personal Statement
The advent of small molecule peptide imaging and therapy is changing the face of oncology diagnosis, prognosis and treatment. This has had a dramatic effect in prostate cancer, with a paradigm shift in clinical practice. At the forefront of this shift in clinical practice, St Vincent’s commenced multiple imaging and therapy trials in prostate cancer using GaPSMA PET and LuPSMA therapy between 2014 and 2018. Having made the move from Nuclear Cardiology in 2012 (culminating in an MD based on publications in the field), to theranostics was a personal paradigm shift in focus that co-incided with the disruptive technology taking place. It has been an incredible opportunity to explore a new weapon in the armament against cancer, well before the rest of the world.
Our prospective trials in LuPSMA therapy, into the diagnostic and prognostic value of PSMA PET and into the manipulability of the PSMA receptor in response to androgen blockade, have been practice changing
My Grants
Research Support (ongoing and completed last 3 years only)
2018-2020: CI CINSW grant for Prostate cancer imaging, genomic and theranostics research $3.75m
2017-2019: AI CINSW grant: Computed tomography (CT) and positron emission tomography (PET)/CT surveillance imaging in asymptomatic Stage III melanoma patients - a prospective cohort study of clinical
benefit and economic implications $500k.
2014-2018: CI Gap2 Movember Grant for PROPS trial : International prospective imaging trial in BCR post RP with MRI, F18 FCH and Ga PSMA.$1.65m
2016-2018: CI Paul Ramsay Foundation Grant for Prospective Lu PSMA trial (completed and in submission) $500K.
2018-2020: AI ANZUP/PCFA/Movember grant $1.5m: TheraP phase II trial – prospective multisite randomized trial comparing LuPSMA vs Cabazitaxel.
2017-2019: CI: Noxopharm funding for prospective phase 1 dose escalation trial in LuPSMA + NOX66 (radiation sensitizer) $ 900K
My Qualifications
|
INSTITUTION AND LOCATION |
DEGREE (if applicable)
|
Completion Date MM/YYYY
|
FIELD OF STUDY
|
|
University of Auckland |
BSc(HONS) |
1989 |
Medicine |
|
University of Auckland |
MBChB |
1991 |
Medicine |
|
Royal North Shore Hospital, Australia |
|
1992-1996 |
Internship, General Medicine/Surgery |
|
The Royal Australasian College of Physicians, Australia |
FRACP |
1996-1999 |
Medical Residency, Medicine |
|
Toronto Western Hospital, Toronto, Canada |
|
2000-2001 |
Nuclear medicine Fellow |
|
Staff Specialist Nuclear Medicine, Concord Hospital, Sydney |
FAANMS |
2001-2012 |
|
|
Auckland University |
MD |
2014 completed |
Thesis in Nuclear Cardiology |
My Research Activities
C. Contribution to Science
Multiple prospective trials and publications in PSMA ligand imaging and therapy in Prostate cancer since 2014.
Modulation of PSMA expression by Androgen deprivation therapy (ADT): Serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade. Emmett L, Joshua A, Epstein R, Ho B, Nguyen Q, Cusick T,Hickey A, Hruby G, Kneebone A, Chalasani V, O’Neill G, Stricker P. SNMMI oral presentation June 2018.
Results of a prospective trial of Lu177 DKFZ 617 PSMA therapy for metastatic castrate resistant prostate cancer : Imaging predictors of treatment response and patterns of progression. Louise Emmett1,2,3, Megan Crumbaker, Bao Ho, Kathy Willowson, Peter Eu, Lalith Ratnayake, Richard Epstein, Ashley Blanksby, Lisa Horvath, Alex Guminski, Kate Mahon, Charlotte Yin, Phillip Stricker, Anthony M. Joshua. (currently in submission Eur Urol Oncol July 2018. Presented WFNMB April 2018)
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. Emmett, L., Willowson, K., Violet, J., Shin, J., Blanksby, A., & Lee, J. (2017).J Med Radiat Sci, 64(1), 52-60.
Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. van Leeuwen, P. J., Emmett, L., Ho, B., Delprado, W., Ting, F., Nguyen, Q., & Stricker, P. D. (2017). BJU Int, 119(2), 209-215. doi:10.1111/bju.1354
Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.
J Nucl Med. 2017 Dec;58(12):1972-1976.
Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Calopedos, R. J. S., Chalasani, V., Asher, R., Emmett, L., & Woo, H. H. (2017). Prostate Cancer Prostatic Dis. doi:10.1038/pcan.2017.23
Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Hruby, G., Eade, T., Kneebone, A., Emmett, L., Guo, L., Ho, B., . . . Kwong, C. (2017). Radiother Oncol, 122(1), 99-102.
Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.Morigi, J. J., Stricker, P. D., van Leeuwen, P. J., Tang, R., Ho, B., Nguyen, Q., . . . Emmett, L. (2015). J Nucl Med, 56(8), 1185-1190.
Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. van Leeuwen, P. J., Stricker, P., Hruby, G., Kneebone, A., Ting, F., Thompson, B., . . . Emmett, L. (2016). (68) BJU Int, 117(5), 732-739. doi:10.1111/bju.13397
Initial multicentre experience of 68 Gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. Siriwardana, A., Thompson, J., van Leeuwen, P. J., Doig, S., Kalsbeek, A., Emmett, L., . . . Stricker, P. (2017). BJU Int. doi:10.1111/bju.13919
Fanti, S., Minozzi, S., Morigi, J. J., Giesel, F., Ceci, F., Uprimny, C., . . . Chiti, A. (2017). Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-017-3725-1
Fendler, W. P., Calais, J., Allen-Auerbach, M., Bluemel, C., Eberhardt, N., Emmett, L., . . . Eiber, M. (2017). 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. doi:10.2967/jnumed.117.190827
Hope TA, Afshar-Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C, Rowe SP.AJR Am J Roentgenol. 2018 Jun 27:1-9
Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.
Hruby G, Eade T, Emmett L, Ho B, Hsiao E, Schembri G, Guo L, Kwong C, Hunter J, Byrne K, Kneebone A.
Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET.
Byrne K, Eade T, Kneebone A, Guo L, Hsiao E, Schembri G, Kwong C, Hunter J, Emmett L, Hruby G.
Radiother Oncol. 2018 Feb;126(2):244-248. doi: 10.1016/j.radonc.2017.10.022. Epub 2017 Nov 10.
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM.
J Nucl Med. 2018 Jan;59(1):82-88
My Research Supervision
Areas of supervision
ILP students
Currently supervising
last supervised 2017
Location
Publications
ORCID as entered in ROS
https://orcid.org/0000-0002-4895-7384